Welcome to our dedicated page for FMTX news (Ticker: FMTX), a resource for investors and traders seeking the latest updates and insights on FMTX stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect FMTX's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of FMTX's position in the market.
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) announced encouraging results from its ongoing Phase 1 trial of etavopivat, a treatment for sickle cell disease (SCD), presented at the EHA 2021 Congress. Key findings include a significant hemoglobin increase of >1g/dL in 73% of patients in the multiple ascending dose cohorts. Initial results from the open-label extension cohort showed that 88% of patients experienced a hemoglobin rise after two weeks of treatment. These promising outcomes support the initiation of the Phase 2/3 Hibiscus Study and reinforce etavopivat's potential efficacy and safety profile.
Forma Therapeutics (NASDAQ: FMTX) announced interim data from its Phase 2 trial of olutasidenib for relapsed/refractory acute myeloid leukemia (AML), to be presented at the 2021 ASCO Annual Meeting. The drug achieved a composite complete remission (CR) or CR with partial hematologic recovery (CRh) rate of 33.3%, with a median duration of response of 13.8 months. Safety data indicated olutasidenib was well-tolerated with common adverse events being febrile neutropenia and anemia. Forma plans to submit a new drug application to the FDA for olutasidenib.
Forma Therapeutics Holdings (Nasdaq: FMTX) announced participation in two upcoming investor conferences. The Oppenheimer Rare & Orphan Disease Summit will take place on May 21, 2021, with Forma’s pre-recorded presentation available at 8:00 a.m. EDT. Additionally, the Jefferies Virtual Healthcare Conference is scheduled for June 1-4, 2021, where Forma will present on June 2 at 11 a.m. EDT. Webcasts of the presentations will be available in the 'News & Investors' section of Forma's website.
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) reported Q1 2021 financial results, highlighting advancements in its clinical pipeline. The company completed the multiple ascending dose phase of its Phase 1 trial for FT-4202 in sickle cell disease, showing a 71% hemoglobin increase in participants. The Phase 2/3 trial, Hibiscus Study, is underway, targeting 344 patients. Additionally, the Phase 1 trial of FT-7051 for metastatic castration-resistant prostate cancer has begun. The company is also preparing a New Drug Application for olutasidenib in acute myeloid leukemia.
Forma Therapeutics Holdings (Nasdaq: FMTX) will release its Q1 2021 financial results on May 14, 2021. The management plans to host a conference call at 8 a.m. ET on the same day to discuss these results and provide a business update. Investors can join the call by dialing specific numbers or through a live webcast on Forma's website.
The company is dedicated to developing innovative therapies for rare hematologic diseases and cancers, aiming to significantly improve patient outcomes.
Forma Therapeutics Holdings (Nasdaq: FMTX) reported its fourth-quarter and full-year financial results for 2020, showcasing significant advancements in its pipeline targeting rare hematologic diseases and cancers. Highlights include promising Phase 1 results of FT-4202 for sickle cell disease, demonstrating a hemoglobin increase in 86% of patients. The company initiated the Phase 1 clinical trial for FT-7051, targeting metastatic castration-resistant prostate cancer. Forma looks forward to pivotal 2021 milestones to further its mission in the biopharmaceutical space.
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) announced new data from its Phase 1 trial of FT-4202, a selective pyruvate kinase-R activator for sickle cell disease (SCD). The trial demonstrated a favorable safety profile and significant efficacy, with 71% of patients achieving a hemoglobin increase of at least 1 g/dL after 14 days of treatment. Notably, activation of PKR improved RBC survival and reduced hemolysis indicators. Further exploration is planned in a Phase 2/3 trial at an upper dosing range of 400 mg, following promising results in both 300 mg and 600 mg cohorts.
Forma Therapeutics Holdings (Nasdaq: FMTX) plans to release its fourth quarter and year-end 2020 financial results on March 30, 2021. The company will host a conference call for the investment community at 8 a.m. Eastern Time on the same day to discuss these results and provide updates on its business operations. Investors can participate by dialing specific numbers for U.S. and international participants or by accessing a live webcast on the company’s official website.
Forma Therapeutics Holdings (Nasdaq: FMTX) is a clinical-stage biopharmaceutical company committed to addressing rare hematologic diseases and cancers. The company will participate in three notable investor conferences: the SVB Leerink 10th Annual Global Healthcare Conference on February 24, the H.C. Wainwright Global Life Sciences Conference on March 9, and the Oppenheimer 31st Annual Healthcare Conference on March 17. Each presentation will be webstreamed on Forma's website, ensuring stakeholders can access real-time updates and insights on their therapeutic advancements.
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX) has announced the dosing of the first patient in a Phase 1 clinical trial for FT-7051, targeting metastatic castration-resistant prostate cancer (mCRPC). The trial will assess FT-7051's safety, tolerability, and initial anti-tumor activity in men who have progressed on prior therapies. Prostate cancer remains a leading cause of cancer death in men, highlighting the critical need for new treatment options. This study aims to provide data on FT-7051's potential benefits for patients facing treatment-resistant prostate cancer.
FAQ
What is the market cap of FMTX (FMTX)?
